Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article
Perrigo's guidance for it's RX Topical business bodes well for its competitor TARO. Perrigo is guiding for 15-19% Growth year on year. This is after registering >30% Year-on-Year growth in the last 4 years. Hopefully, TARO's management will update it's guidance and trash the highly inaccurate June 14th estimates.
No comments:
Post a Comment